Philips on Wednesday posted worse-than-expected losses in 2024, as the Dutch medical device maker bids to turn the page on a ...

Philips shares took a hit today on fourth-quarter results that included potentially concerning performance in China.

We took significant steps to address the consequences of the Respironics recall. We know there's more to do and are very focused on driving further improvements. More recently, Philips Respironics ...

The company said, ” Philips remains focused on successfully executing its three-year plan to drive operational improvements and crea ...

Philips forecast a double-digit sales decline in China for the first half of 2025 after reporting “significant deterioration” ...

Philips on Wednesday posted worse-than-expected losses in 2024, as the Dutch medical device maker bids to turn the page on a ...

In December 2024, Philips Respironics obtained final approval for the recall-related medical monitoring settlement, and in February 2025, the personal injury settlement became final following a ...

Philips ended 2024 deep in the red, suffering a loss of 698 million euros, the health tech company announced on Wednesday.

European markets opened in mixed territory Wednesday, with investors assessing more earnings releases and the latest U.K.

Reports Q4 revenue EUR 5.04B vs. EUR 5.06B last year. Reports Q4 comparable sales up 1%. The company said, “We delivered better care for more ...

Philips on Wednesday posted worse-than-expected ... fundamentals and resolved significant US litigation relating to the Respironics recall," said Jakobs. Looking ahead, the firm said it expected ...

The outlook includes the impact of the recently announced US-China tariffs. It excludes ongoing Philips Respironics-related legal proceedings, including the investigation by the US Department of ...